Mural Oncology plc

$2.04+0.00%(+$0.00)
TickerSpark Score
59/100
Mixed
100
Valuation
20
Profitability
60
Growth
84
Health
30
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MURA research report →

52-Week Range29% of range
Low $0.95
Current $2.04
High $4.74

Companywww.muraloncology.com

Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs.

CEO
Caroline J. Loew
IPO
2023
Employees
116
HQ
Dublin, IE

Price Chart

-49.63% · this period
$4.47$2.73$1.00Dec 06Jun 11Dec 09

Valuation

Market Cap
$35.38M
P/E
-0.30
P/S
0.00
P/B
0.64
EV/EBITDA
0.17
Div Yield
0.00%

Profitability

Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
-131.47%
ROIC
-179.73%

Growth & Income

Revenue
$0 · 0.00%
Net Income
$-128,514,000 · 38.05%
EPS
$-7.58 · 39.02%
Op Income
$-138,262,000
FCF YoY
34.93%

Performance & Tape

52W High
$4.74
52W Low
$0.95
50D MA
$2.08
200D MA
$2.37
Beta
2.96
Avg Volume
170.82K

Get TickerSpark's AI analysis on MURA

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Dec 5, 25Hickey Benjaminsell15,021
Dec 5, 25Hickey Benjaminsell8,637
Dec 5, 25Hickey Benjaminsell8,462
Dec 5, 25Loew Carolinesell293,059
Dec 5, 25Loew Carolinesell379,690
Dec 5, 25Loew Carolinesell134,225
Dec 5, 25Loew Carolinesell90,025
Dec 5, 25Cuss Francis Msell8,637
Dec 5, 25Cuss Francis Msell8,462
Dec 5, 25Cuss Francis Msell15,021

Our MURA Coverage

We haven't published any research on MURA yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate MURA Report →

Similar Companies